Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad26.CS.01
- Development stage
- Phase 2
- Lead developer
- Janssen Pharmaceutical
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ad26.CS.01 is an experimental viral vector vaccine developed for the prevention of malaria. It utilizes a replication-deficient recombinant adenovirus serotype 26 (Ad26) vector to deliver the Plasmodium falciparum circumsporozoite (CS) protein, which is the primary surface protein of the malaria parasite during the sporozoite stage. The vaccine is produced using the proprietary AdVac technology and PER.C6 cell line. It is designed to stimulate both humoral and cellular immune responses to prevent the parasite from infecting liver cells. In clinical development, Ad26.CS.01 has been evaluated as a booster component in heterologous prime-boost regimens, specifically following priming with Ad35.CS.01. Although Phase 1/2a trials confirmed the vaccine's safety and immunogenicity, it demonstrated limited protective efficacy against controlled human malaria infection.
- Other names
- Ad26.CSAd-26.CSAd 26.CS
02
Targets
CSP (Circumsporozoite protein)
Beyond the preview
Go deeper on Ad26.CS.01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad26.CS.01.